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There is growing evidence that male as well as female reproductive function has been declining in human and wildlife popula-
tions over the last 40 years. Several factors such as lifestyle or environmental xenobiotics other than genetic factors may play a role
in determining adverse eﬀects on reproductive health. Among the environmental xenobiotics phthalates, a family of man-made
pollutants are suspected to interfere with the function of the endocrine system and therefore to be endocrine disruptors. The def-
inition of endocrine disruption is today extended to broader endocrine regulations, and includes activation of metabolic sensors,
such as the peroxisome proliferator-activated receptors (PPARs). Toxicological studies have shown that phthalates can activate a
subset of PPARs. Here, we analyze the epidemiological and experimental evidence linking phthalate exposure to both PPAR acti-
vation and adverse eﬀects on male and female reproductive health.
Copyright © 2008 Giuseppe Latini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The phthalate esters are a class of water-insoluble, high-
production-volume, synthetic organic chemicals used widely
in a variety of industrial applications, including personal-
care products (e.g., perfumes, lotions, cosmetics), paints,
and mainly as plasticizers to confer ﬂexibility and dura-
bility to polyvinyl chloride- (PVC-) based plastics and to
make the plastic appropriate to diﬀerent uses, including
food, construction industry, medical devices, and phar-
maceuticals since about the 1930s [1–4]. However, these
plasticizers are not chemically bound to the plastic prod-
ucts, but leak out from PVC items into the environment
with time and use. As a consequence, they have been
found everywhere in the environment and are universally
considered ubiquitous environmental contaminants. Di-(2-
ethylhexyl) phthalate (DEHP) is the most abundant phtha-
late in the environment and mono-(2-ethylhexyl) phtha-
late (MEHP) is its primary metabolite [1–4]. Other impor-
tant phthalates production- and applicationwise are diethyl
phthalate (DEP), dibutyl phthalate (DBP), di-iso- and di-
n-butyl phthalate (DiBuP, DnBuP), butyl-benzyl phthalate
(BBP), di-isononylphpthalate (DiNP) and di-n-octyl phtha-
late (DnOP) [5]. Humans are exposed to phthalates for their
whole lifetime, since intrauterine life [6–11].
The ability of these pollutants to aﬀect human health is
a major concern. In particular, evidence suggestive of harm-
ful eﬀects on the male reproductive system and related out-
c o m e sh a v eg r a d u a l l ya c c u m u l a t e di nr e c e n ty e a r s .I na d -
dition, there is wide demonstration that reproductive func-
tions are altered by endocrine disrupting chemicals (EDCs),
including phthalates. These chemicals have been found to2 PPAR Research
interfere with the function of the endocrine system, which is
responsible for growth, sexual development, and many other
essential physiological functions in both genders.
EDCs can act genomically, with agonistic or antagonistic
eﬀects on steroid receptors and may alter reproductive func-
tion and/or cause feminization by binding to oestrogen or
androgen receptors. However, EDCs can also act by nonge-
nomic mechanisms, altering steroid synthesis [12, 13].
The deﬁnition of endocrine disruption is today extended
to broader endocrine regulations, and includes activation of
metabolic sensors, such as a subset of nuclear hormone re-
ceptor superfamily members called peroxisome proliferator-
activated receptors (PPARs).
To this regard, a large group of industrial and pharma-
ceutical chemicals, including phthalates, are known for their
ability to provoke peroxisome proliferation, thus increas-
ing both the size and number of peroxisomes [14]. Perox-
isomes are essential organelles of eukaryotic origin, ubiqui-
touslydistributedincellsandorganisms,whichperformvar-
ious metabolic functions (peroxide-derived respiration, beta
oxidation of fatty acids, cholesterol metabolism, etc.) within
the cell [15].
Many of the adaptive consequences for exposure to these
pollutants are mediated by PPARs, members of the nuclear
hormone receptor (NRs) superfamily of ligand-activated
transcription factors. They are activated by binding of nat-
ural ligands, such as polyunsaturated fatty acids or by syn-
thetic ligands. Three subtypes of PPARs (alpha, beta, and
gamma) have been identiﬁed in diﬀerent tissues, encoded by
separate genes [16].
Several studies in recent years have revealed their impor-
tance in both normal physiology and in the pathology of var-
ious tissues [17, 18]. In particular, human and animal stud-
ies have demonstrated that PPARs are important in placental
development [19],whiletheyarebelievedto playanessential
role in the adverse eﬀects elicited by EDC [20].
The aim of this review is to explore how much evi-
dence exists linking phthalate exposure, PPARs activation,
andeventualactionsofPPARsasmediatorsofenvironmental
toxic substances for reproductive function in both genders.
2. ENVIRONMENTAL DISSEMINATION AND
EPIDEMIOLOGICAL EVIDENCE OF
PHTHALATE REPRODUCTIVE TOXICITY
Globally, more than 18 billion pounds of phthalates are used
each year and well above two million tons of DEHP alone
are produced annually worldwide [21]. Given their high pro-
duction volume, common use, and widespread environmen-
tal contamination, humans are exposed to these compounds
through ingestion, inhalation, and dermal exposures on a
daily basis as testiﬁed by detection of phthalates in serum,
seminalﬂuid,amnioticﬂuid,breastmilk,andsaliva[5,9,22–
24] .T h e s es t u d i e sh a v ep r o v i d e de v i d e n c eo nt h er e l a t i v e l y
high variation of phthalate exposure from day to day within
individuals as well as between ethnic groups, geographic ar-
eas, and ages. In particular, general population can be ex-
posed to DEHP to a much higher extent than previously be-
lieved and an exposure of children, twice as high as the ex-
posure of adults with respect to their body weight, has been
observed [23–26].
In particular, higher DEHP exposure has been docu-
mented in neonatal intensive-care-unit infants, because of
multiple medical device-related DEHP exposure [27].
In addition, Blount et al. [28] found that women of re-
productiveagehadsigniﬁcantlyhigherurinarylevelsofMBP
(a reproductive and developmental toxicant in rodents) than
other age/gender groups. However, in spite of the alarm-
ing wide environmental diﬀusion and use, studies in human
populations suggesting an association between phthalate ex-
posure and adverse reproductive health outcomes are limited
yet.
Tothisregard,chronicoccupationalexposuretohighlev-
els of phthalates is associated with decreased rates of preg-
nancyandhigherratesofmiscarriageinfemalefactorywork-
ers [29, 30]. Correspondently, higher urinary phthalate lev-
els were observed to correlate with pregnancy complications
such as anemia, toxemia, and pre-eclampsia in women liv-
ing near a plastics manufacturer [31]. In addition, signiﬁ-
cantly high levels of phthalates were identiﬁed in girls with
thelarche,suggestinganassociationbetweenplasticizerswith
known estrogenic and antiandrogenic activity and the cause
of premature breast development in a human female popu-
lation [32].
In utero exposure to phthalates has been shown to be sig-
niﬁcantlyassociatedwithashorterpregnancyduration[7,8]
and it has been hypothesized that phthalates may play a role
in inducing and/or potentiating an intrauterine inﬂamma-
tory response, a well established risk factor for prematurity
[33]. Moreover, an association between phthalate exposure
and endometriosis has been shown, suggesting a potential
role for phthalate esters in the pathogenesis of this common
cause of female infertility [34, 35]. More speciﬁcally to the
male reproductive system, phthalate exposure seems to be
tightly correlated to the impairment of androgen activity.
For example, phthalate monoesters levels in breast milk re-
sulted to be correlated with hormone levels in healthy boys,
whichwereindicativeoflowerandrogenactivityandreduced
Leydig cell function [36], and professional long-term expo-
sure to phthalates has been reported to be associated with al-
teredsemenquality[37,38]anddecreasedserum-freetestos-
terone [39].
In addition, impaired testicular descent and decreased
anogenital distance (AGD), the most sensitive marker of an-
tiandrogen action in toxicological studies and a sensitive
measure of prenatal antiandrogen exposure have been re-
ported in boys whose mothers had elevated prenatal phtha-
late exposure [43]. All together, these ﬁndings suggest an im-
pairment of sex hormone balance by prenatal and postna-
tal phthalate exposure but, although suggestive of the po-
tentially dangerous eﬀects of phthalate exposure on human
health, they are not conclusive yet, and more epidemio-
logic data are needed in human populations along with a
better mechanistic understanding of the phthalates activ-
ities. Although the possible mechanism of action by ph-
thalates remains, to date, largely obscure, the use of ani-
mal models have enormously contributed to characterize theGiuseppe Latini et al. 3
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reproductive toxicity proﬁles of phthalates and to highlight
the mechanisms possibly involved.
3. MALE AND FEMALE REPRODUCTIVE TRACT
DEVELOPMENT: POSSIBLE INTERFERENCE SITE
BY PHTHALATES
Male and female reproductive tract development is a dy-
namic process, requiring the production and the ﬁne reg-
ulatory activity of sex steroid hormones: androgens, estro-
gens, and the progestagens [40]. Steroidal sex hormones reg-
u l a t ef o e t a ld e v e l o p m e n t a lp r o c e s s e ss u c ha sd i ﬀerentiation
and sex determination. The major sites of synthesis of the
sex steroids are corpus luteum for progestagens, testis for an-
drogens, and ovaries for estrogens.
The biosynthesis of sex steroids is catalyzed by a se-
ries of enzymes that form the steroidogenic pathway [41].
Thispathwaycausestheconversionofpregnenolone(choles-
terol derivative key steroidogenic intermediate common to
all classes of steroid hormones) to progesterone, the precur-
sor for the testosterone that is formed in testis by Leydig
cells through two ways: (1) Δ4-biosynthesis leads to proges-
terone,17-α-hydroxyprogesterone,andandrostenedione;(2)
the Δ5-biosynthesis leads to 17-α-hydroxypregnenolone, de-
hydroepiandrosterone, and Δ5-androstendiol [41].
Androgens themselves can then be transformed to es-
trogens. The extent to which this biotransformation takes
place depends on the expression of the various enzymes
in speciﬁc tissues. The enzyme complex 19-hydroxylase-
aromatase, which catalyzes the conversion of androgens to
estrogens, plays a major role in this biotransformation [42].
The development of mammalian foetus into a male re-
quires the production and action of steroid hormones, no-
tably androgens and antimullerian hormone after testis for-
mation, in contrast to the female development, a process
largely hormone-independent [43].
Moreover, the mature reproductive function is under the
regulation of the hypothalamus-pituitary-gonadal (HPG)
axis. The limbic system of the brain releases speciﬁc neuro-
transmitters or neuropeptides that stimulate the hypothala-
mus to produce gonadotropin-releasing hormone (GnRH)
which stimulates the pituitary gland to release speciﬁc hor-
mones (gonadotrophins) that are transported via the blood
stream to hormone-synthesizing tissues [44]. In the case
of mammals, the gonadotrophins from the pituitary gland
are luteinizing hormone (LH) and follicle-stimulating hor-
mone (FSH). Under the inﬂuence of these substances, sex
steroids, that is, estrogens and androgens, are released into
the blood circulation from the ovaries and the testis, respec-
tively. Negative feedback from the concentration of these go-
nadal steroids in the blood can lower or block the release of
GnRH from the hypothalamus and of gonadotrophins at the
pituitary level, thus modulating HPG axis [44].
Keeping this in mind, it might be expected that any envi-
ronmental, hormonally active chemicals capable of perturb-
ing the adequate production and action of sex hormones or
the balance between estrogens and androgens during foetal
life have the potential to interfere with one or more critical
aspects of reproductive function (Figure 1).
4. PRE- AND POSTNATAL DEVELOPMENTAL AND
REPRODUCTIVE TOXICITY BY PHTHALATES
Chronic exposure of laboratory animals to phthalates has
been reported to lead to severe adverse eﬀects, including
foetal death, carcinogenesis, teratogenesis, and hepatotoxic-
ity [45–47]. In particular, a wide range of developmental and
reproductive toxicities in mammals are induced by phtha-
lates. Phthalates can directly aﬀect fetal and neonatal testis
diﬀerentiation, inducing male rat reproductive tract malfor-
mations, as well as testicular changes remarkably similar to
testicular dysgenesis syndrome (TDS) in humans [48–52].
Testicular dysgenesis, or abnormal testicular develop-
ment, after in utero phthalate exposure has been shown to be4 PPAR Research
associatedwithabnormalfunctionofbothSertoliandLeydig
cells and abnormal sex organs development [52, 53].
Sertolicellsplayacriticalroleinfoetaltestisdevelopment
regulating the dynamic process of movement, organization,
diﬀerentiation of all the cell types within the testis [54]. As
a consequence, the abnormal function of Sertoli cells associ-
ated with phthalate exposure [52, 53] might alter the diﬀer-
entiation signals normally implicated in tissue morphogen-
esis, thus leading to many of the histological and functional
anomalies observed in TDS (Figure1).
Leydig cells, the principal providers of steroid hormones
in the testis, are also targeted by phthalates. To this regard,
the highly conserved role of testosterone and dihydrotestos-
terone (DHT), in driving male reproductive tract develop-
ment (masculinization) is well known. As a consequence, in
rodents the whole period of male genital tract diﬀerentia-
tion is particularly susceptible to the eﬀects of antiandro-
gens, as demonstrated by in utero exposure to ﬂutamide,
(a well-known androgen receptor antagonist) and phthalates
both inducing abnormalities of androgen-regulated sexual
diﬀerentiation [49]. In addition, the administration of syn-
thetic estrogens, such as diethylstilboestrol (DES), to preg-
nant women and rodents causes reproductive tract abnor-
malities in the oﬀspring, including cryptorchidism, [55]a s
well as a dose-dependent reduction in the number of Sertoli
cells critically involved in spermatogenesis [56]. The ability
of estrogens to reduce androgen levels or expression of an-
drogen receptor is relevant [57]. These results suggest that
abnormalintrauterinehormonelevelswithdecreasedandro-
gen production/action or increased estrogens levels may play
a role in determining adverse eﬀects on reproductive health.
Correspondently, critical to the induction of phthalate testic-
ulartoxicityistheconsiderablereductioninfetalandpostna-
tal testosterone levels observed after in utero exposure to ph-
thalates at the critical window for the androgen-dependent
reproductivetractdevelopment[49,52,53,58].Inparticular,
the exposure to DEHP decreases testosterone to levels simi-
lar to those normally found in females leading to incomplete
masculinization and hypospadias and cryptorchidism [58].
Thus, several phthalate esters have been shown to carry out
“antiandrogenic” activity through a mechanism that is dis-
tinct from androgen-receptor antagonism, that is, targeting
the Leydig cells testosterone biosynthesis machinery. In ad-
dition, genes directly associated with testosterone biosynthe-
sis are uniformly downregulated by phthalate exposure in
the fetal testis [59]. These steroidogenic genes include those
involved in cholesterol handling, such as scavenger receptor
class B type 1 (SR-B1) implicated in the selective cholesterol
esters uptake from high density lipoproteins, steroidogenic
acute regulatory protein (StAR), that mediates cholesterol
transport across the mitochondrial membrane, the rate lim-
iting enzyme in testosterone biosynthesis, that is, cholesterol
side-chain cleavage enzyme (P450scc), that converts choles-
terol into pregnenolone, 3β-hydroxysteroid dehydrogenase
(3βHSD), and CYP17α [59, 60]. In addition, phthalates al-
ter the expression of genes encoding sex steroid metaboliz-
ing enzymes in the gonads and peripheral organs such as the
liver. Among these, 5α-reductase, that converts testosterone
to DHT, was upregulated by DEHP in the prepubertal rat
testis [61]. Aside from the interference with steroid synthe-
sis and metabolism, the induction of cryptorchidism by ph-
thalates is mediated by the alternative mechanism acting at
the initial hormone-independent phase of testicular descent.
Phthalates have indeed been shown to alter the expression of
insulinlike hormone 3 (Insl3) in fetal Leydig cells [62],which
playsaroleinguidingthetestisduringitsﬁrstphaseoftrans-
abdominal descent.
In postnatal exposure, a strong species diﬀerence in the
phthalate responsiveness is evident, with some species (Syr-
ian hamsters, e.g.,) more resistant to phthalate toxicity possi-
bly as a consequence of an ineﬃcient metabolic transforma-
tion of diesters to monoesters [63]. Younger animals result,
in general, more sensitive than adult ones [64]. For exam-
ple, Grey observed a decrease in seminiferous tubule diam-
eter in testis and accessory sex organs (seminal vesicle and
prostate) weight after phthalate exposure in 4-week-old, but
not in 15-week-old rats [64]. These eﬀects were associated
with the induction of apoptosis in germ cells, likely as a con-
sequence of an increased generation of oxidative stress and
concomitant alteration of antioxidant defences by phthalate
[65].Correspondently,theFSHsignallingpathwayforSertoli
cell proliferation and diﬀerentiation resulted to be impaired
after phthalate exposure [66, 67].
Also in postnatal and adult rats phthalates aﬀected
steroid hormone synthesis and metabolism, as indicated by
decreased testosterone serum levels in male rats acutely ex-
posed to some active phthalates and by a decreased testos-
terone secretion by cultured Leydig cells treated with MEHP
[68]. However, contrasting results were observed by Ak-
ingbemi et al. [69] and Eagon et al. [70] in male rat chron-
ically exposed to environmentally relevant low levels of
DEHP. Increased LH and testosterone serum levels together
with an increased serum estrogen likely due to impaired Ley-
dig cell steroidogenesis and compensatory Leydig cell prolif-
erationwereobserved.Themodulationbyphthalateofmany
estrogen metabolizing enzymes seems to be very complex,
since it has been reported both a downregulation [71, 72]
and an upregulation [73] of the aromatase gene after phtha-
late exposure, depending on the cell type analyzed.
Overall, the data presented here demonstrated that cer-
tain phthalates like other environmental chemicals are capa-
ble of disrupting male reproductive tract organogenesis and
function when administered to laboratory animals during
pregnancy and/or postnatal life, producing types of malfor-
mations and histological changes causing infertility remark-
ably similar to those observed in human TDS. One mecha-
nism responsible for this eﬀects may be the ability to disrupt
the endocrine balance, that is, androgen/estrogen activities,
essential for reproductive system development and home-
ostasis, acting as environmental antiandrogen compounds
[74]. Although this raises concern towards other factors such
as lifestyle that might have inﬂuenced human fertility [75].
5. THEPPARSYSTEMATTHECROSSROADSBETWEEN
METABOLISM AND REPRODUCTION
The identiﬁcation of phthalates as environmental chemicals
belonging to the family of peroxisome proliferators (PP) hasGiuseppe Latini et al. 5
shed new insight into the potential molecular mechanism
of phthalate action in the reproductive system of mammals.
The pleiotropic eﬀects induced by PP including phthalates
in the rodent liver are mediated by the activation of PPARs,
ligand-activated transcription factors belonging to the nu-
clear receptor superfamily, which also includes the steroid
and thyroid hormone receptors [76]. Thus far, three PPAR
isoforms (α, β,o rδ,a n dγ), encoded by separate genes,
have been identiﬁed in various tissues, with PPARα pre-
dominantly expressed in the liver, PPARγ in adipose tissue,
and PPARβ in a wider range of tissue [16]. Upon activa-
tion by their lipophilic ligands, PPARs regulate gene tran-
scription by binding to PPAR response elements (PPRE)
within the promoter of target genes as heterodimers with
retinoic X receptors (RXR) [16, 77]. PPARs can also repress
gene expression in a DNA-binding-dependent way through
the recruitment of corepressors to unliganded PPARs as
well as in a DNA-binding-independent manner by inter-
fering with other nuclear signalling pathways via protein-
protein interaction (leading to formation of inactive com-
plexes) or via competition for limiting amounts of the het-
erodimerization partner RXR or coactivators [78]. Fatty
acids and eicosanoids have been identiﬁed as natural lig-
ands for PPARs. More potent synthetic PPAR ligands in-
clude the ﬁbrate and thiazolidinedione drugs, clinically used
as hypolipidemic and antidiabetic agents, respectively. Since
the discovery of PPARs in 1990 [17], several functions
have been attributed to these receptors. PPARs play criti-
cal physiological roles regulating lipid and glucose home-
ostasis, cellular diﬀerentiation, proliferation, and the inﬂam-
matory/immune response, with subsequent clinically rele-
vant implication in several diseases including dyslipidemia,
diabetes, cancer, atherosclerosis. PPARα has been demon-
strated to play a role in regulating lipid catabolism, whereas
PPARγ controls adipocyte diﬀerentiation and lipid storage
[16, 77]. Although PPARβ is less well understood, it might
be a mediator in the control of brain lipid metabolism,
fatty acid-induced adipogenesis, and atherogenic inﬂamma-
tion [77]. Given the extensive crosstalk between PPARs and
other transcription factors and signalling events regulating
energy balance, diﬀerentiation and other signiﬁcant physi-
ological processes in many tissues, the involvement of en-
vironmental chemicals in the PPAR system may potentially
result in pathophysiologically relevant consequences for hu-
man health.
T h er o l eo fP P A R α in PP-induced hepatic proliferative
responses was established by the development of PPARα-
deﬁcient mice by Lee et al. [79]. In contrastto wild-type con-
trol animals, PPARα homozygous-deﬁcient mice do not ex-
hibit hepatic peroxisomal proliferation in response to treat-
ment with PP. Aside from modest changes in lipid proﬁle
and weight, PPARα-deﬁcient mice are otherwise phenotyp-
ically normal [80]. Thus, the major hepatic eﬀects of PP, in-
cluding hepatocarcinogenic eﬀects, are mediated by PPARα-
dependent gene transcription and signalling events. The re-
sponse to PP seems to be species-speciﬁc, with rats and mice
being quite sensitive to them and humans, guinea pigs, and
other species being refractory [80]. Remarkably, the hepato-
toxic eﬀects of PP are lost in humans due to the lower level
of PPARα expression in human liver than in rodent one [81]
and to species-speciﬁc responsiveness of PPARα [82].
Before focusing on the potential involvement of PPARs
in the reproductive eﬀects of phthalate, it would be useful
to consider PPAR expression pattern in the reproductive sys-
tem, since the potential PPAR-mediated eﬀects of phthalates
depend on tissue distribution of the PPAR isoforms and the
PPAR-responsive genes in each tissue. All PPAR isoforms are
expressed in the central nervous system and in reproductive
tissues, such as gonads (testis and ovary), uterus, prostate,
mammary gland, pituitary gland [83]. In the testis, both so-
matic and germ cells express PPAR isoforms: PPARα and β
are expressed in Leydig cells and cells of seminiferous tubule
(Sertoli cells and germ cells) [60, 84], while PPARγ seems to
be only detectable in Sertoli cells, although weak PPARγ ex-
pression in germ cells has recently been reported [85]. All
PPAR isoforms have been detected in the ovary [84]. PPARγ
is the predominant isoform expressed in the granulosa cells
andpreovulatoryfollicles,butitsexpressionfallsaftertheLH
surge [86]. In addition, PPARγ is less strongly expressed in
the techal cells and in corpus luteum where it increases af-
ter ovulation [86]. However, in the absence of fertilization or
embryoimplantation,PPARγ expressiondecreasesasaresult
ofcorpusluteumregression[87].Finally,PPARγ isexpressed
in uterine tissue, blastocyst and, together with PPARα and β,
in gestational tissues [88, 89].
The physiological role of PPARs in the reproductive tis-
sues is not completely understood but while, on one hand,
PPARα-null mice remain viable and fertile [79], on the other
hand, PPARβ deletion impairs fertility [90]a n dP P A R γ-null
mutation is even embryonically lethal [91]. Indeed, recent
ﬁndings suggested putative important roles for PPARs in re-
productive system: the ability of PPARs to regulate energy
balance may represent a potential molecular link between re-
productive function and glucose and lipid metabolism. It has
been shown that PPARα, whose expression is upregulated by
FSH in cultured seminiferous tubules [92], may aﬀect sper-
matozoa fertility by promoting lipid storage mobilization
and modifying phospholipid composition. PPARβ seems to
play an important role in embryo implantation as showed
by its strong upregulation during the decidualization process
and the appearance of placental malformations in PPARβ-
null mice [90]. Finally, several lines of evidence suggest that
PPARγ is critically involved in follicular development, ovula-
tion, maintenance of corpus luteum during pregnancy, and
m a t u r a t i o na n df u n c t i o no fp l a c e n t a[ 83].
6. MECHANISM OF PHTHALATE ESTER
REPRODUCTIVE TOXICITY:
POTENTIAL ROLE OF PPARS
The involvement of phthalate-PPAR interactions in the re-
productive biology alteration derives from recent ﬁndings
demonstratingthatphthalatesareabletoactivatePPARαand
PPARγ isoforms. Metabolic conversion of diesters to the hy-
drolytic monoesters seems to be essential to obtain PPAR ac-
tivation and toxicological eﬀects [93]. Indeed, hepatic perox-
isomal proliferation and the associated hepatocarcinogenic
response induced in rodents by DEPH are mediated by its6 PPAR Research
bioactive metabolite MEHP [94], which is able to activate
both human and rodent PPARα and PPARγ in in vitro trans-
activationassay[95].InadditiontoMEHP,otherstructurally
diverse phthalate monoesters, most notably monobenzyl ph-
thalate (mBzP), the primary metabolite of butyl benzyl ph-
thalate (BBP), and mono-sec-butyl phthalate (MBuP) are ca-
pable of activating both human PPAR isoforms and target
genes [93, 96] with potential implication for human health
as these reproductive toxicants have been detected in human
urinesamplesatexceptionallyhigherlevelsthanMEHPitself
[28]. However, it has been recently found that the diesters
DEHP and BBP themselves were able to activate PPARα and
PPARγ to some extent, although it was likely attributable to
low level of esterases activity in the cell model used [96].
Interestingly, analyses of structure-activity relationship have
found that PP in general are amphipathic carboxilates thus
resembling natural PPAR ligands such as long-chain satu-
rated and unsaturated fatty acids [97] .T h ec a r b o x y lm o i e t y
ofmonoestersiscriticalforligandactivity:forexample,some
DEHP metabolites, such as MEHP and 2-ethylhexanoic acid,
aremorepotentPPARactivatorsthan2-etylhexanolmetabo-
lite [98]. The rank order for phthalate activation of mouse
and human PPARα and PPARγ agrees with the relative abil-
ity of phthalate esters to induce the classical PPAR responses,
that are liver peroxisomal proliferation in rodents for PPARα
and adipocyte diﬀerentiation for PPARγ [93, 99]. Indeed,
it has been found that esters with long and branch-side
chain are more potent PPAR activators than those contain-
ing short-chains or straight-chains. As regards PPARβ,o n l y
phthalate monoesters with longer and branch-side chains
can activate this isoform but at a concentration higher than
that required for activation of PPARα and PPARγ [100].
Importantly, human PPARs are less sensitive to phthalate
monoesters than the corresponding mouse receptors [93].
SincetheactivationofPPARassessedbytransactivationassay
might result from indirect events, such as endogenous pro-
duction of a metabolite from the test compound or release of
endogenous ligand, these compounds had to be tested fur-
ther for direct binding to the PPARs. Although activation of
PPARs by some phthalates may occur indirectly through re-
lease of endogenous lipid activators (fatty acids) from car-
rier proteins, notably fatty acid binding protein (FABP) or
through a yet unidentiﬁed intermediate factor [101], recent
ﬁndings reported that some relevant monoester phthalates
areableofdirectlybindingPPARαandPPARγ receptors[96].
Consistent with their ability to activatePPARsin transactiva-
tion assay, BBP and DBP weakly interact with both isoforms.
Although in most cases there has been found a correla-
tion between PPAR activation by phthalate monoesters and
reproductive toxicity by the corresponding diesters, there
exist also ﬁndings weakening the assumption of a general
obligatory role for PPARs in mediating phthalate-induced
reproductive eﬀects. For example, while di-isononyl phtha-
late (DINP) is a weak reproductive toxicant [102], its mo-
noester metabolite MINP is a moderately strong PPAR acti-
vator [100]. In addition, DBP is a strong reproductive tox-
icant through its proximal metabolite MBP [103] and in-
duces hepatotoxicity in rodents via PPARα [104], although
MBP only weakly activates PPARs in transactivation assay
[93]. One possible interpretation of these discordant results
may be the involvement of an indirect mechanism of PPAR
activation mediated by an unknown endogenous metabolite
activator, not necessarily detectable by using transactivation
assay.
Only a few studies in PPARα-null mice directly de-
termined the role of PPAR in phthalate-induced male de-
velopmental and reproductive toxicities. The study by Pe-
ters et al. [105] showed that prenatal exposure to DEHP
caused developmental malformations in both wild-type
and PPARα knockout mice, thus suggesting a PPARα-
independent mechanism. However, it is diﬃcult to draw any
conclusion about the role of PPARα in phthalate reproduc-
tive toxicity since the intrauterine administration of DEHP
occurred before the critical period of reproductive tract dif-
ferentiation. Another important animal study demonstrated
that intrauterine DEHP-treated PPARα-deﬁcient mice, pre-
dominantly normal at earlier time point, developed delayed
testicular, renal and developmental toxicities, but not liver
toxicity, compared to wild types [104], thus ﬁrst conﬁrm-
ing the early observation by Lee et al. about the PPARα de-
pendenceofliverresponseand,moreimportantly,indicating
that DEHP may induce reproductive toxicity through both
PPARα-dependent and -independent mechanism. Another
study found that the administration of DEHP resulted in
milder testis lesions and higher testosterone levels in PPARα-
null mice than in wild-type mice [106]. In contrast, the
PPARα-independent reproductive toxicity observed by Ward
et al. may conceivably be mediated by other PPAR isoforms,
such as PPARβ and PPARγ, or by a nonreceptor-mediated
organ-speciﬁc mechanism. Unfortunately, till now no stud-
ies have been performed in PPARβ-null mice, and the toxi-
cological impacts of phthalates that activate PPARγ are un-
known. Determining a role for PPARγ in phthalate-induced
reproductive toxicity requires testis-speciﬁc-knockout mice
as PPARγ deletion results in the death of the embryo [91].
Notably, both PPARα and PPARγ are responsive to DEHP
in vitro and are translocated to the nucleus in primary Ser-
toli cells after incubation of these cells with phthalate esters
[107, 108]. Given the key role played by Sertoli cells in driv-
ing testis morphogenesis, it may be therefore hypothesized
that the impairment of this cell type by MEHP contributed
to the observed testicular toxicity.
The potential of PPARs to mediate the endocrine disrup-
tion activity by phthalates is also suggested from the ﬁnd-
ing that a few genes involved in steroid biosynthesis and
metabolism are directly regulated by PPARs. MEHP acti-
vates both PPARα and PPARγ in cultured rat granulosa cells
which cause a complete inhibition of aromatase gene expres-
sion [109–111]. In addition, the estradiol metabolizing en-
zyme 17β-HSD IV has been shown to be induced by MEHP
in the liver and granulosa cells through a PPARα-dependent
mechanism [112]. Therefore, both decreased estradiol syn-
thesis and increased estradiol metabolism contribute to sup-
pressed serum estradiol levels observed after DEHP in vivo
exposure and to the subsequent female reproductive toxicity
[71, 72, 113]. Finally, the induction by DEHP of FABP ex-
pression in the liver via PPARα [114] and in granulosa cells
viabothPPARαandPPARγ [115] may play important role inGiuseppe Latini et al. 7
Table 1: Structures and related name of the most common phthalate monoesters. Diesters of o-phthalic acid are quickly metabolized in vivo
to their active metabolites, the monesters. The length and structure of the side chain are important for toxicity.
Chemical structure Systematic name Abbreviation
O
O
O
O
CH3
H
Monomethyl phthalate MMP
O
O
O
O
CH3
H
Monoethyl phthalate MEP
O
O
O
O
CH3
H
Monobutyl phthalate MBP
O
O
O
O
CH3
H
Monopentyl phthalate MPP
O
O
O
O
CH3
H
Monohexyl phthalate MHP
O
O
O
O
CH3
H
Monopropyl phthalate MPrP
O
O
O
O
CH3
CH3
H
Mono-(2-ethylhexyl) phthalate MEPH
the mechanism of phthalate eﬀect on steroid hormones since
FABPfunctionsasanintracellulargatewayforPPARagonists
[116] and as a donor of potential fatty acid ligands of PPARs
[101].
Taking into account the speciﬁc tissue distribution and
thephysiologicalrolesofPPARisoforms,onecouldspeculate
upon some phthalate eﬀects in mammals. It is known that
cells exposed to PP undergo oxidative stress possibly due to
PPARα-mediated activation of metabolizing enzymes in the
liver and associated with the hepatic toxicity of DEHP [117].
Genes involved in oxidative stress response have been shown
to be upregulated in the liver by DEHP exposure [118]. In8 PPAR Research
addition, the induction of xenobiotic metabolizing enzymes
by PPARα after DEHP exposure could increase the suscepti-
bility to other environmental toxicants requiring metabolic
activation [118]. PPARγ is a prototypic adipocyte diﬀerenti-
ation regulator [119] and activation of PPARγ by phthalates
in other tissue and subsequent alteration of diﬀerentiation
pathways may be implicated in phthalate teratogenic eﬀects.
Inaddition,PPARγ maybepartoftheLH-inducedluteiniza-
tion in the ovary since its activation causes aromatase down-
regulation, this event being essential for the postovulatory
phenotype [120]. The activation of PPARγ by phthalates in
thepreovulatoryfolliclepreventedtheestradiolincreasenec-
essary for stimulating the ovulatory surge of LH and prema-
turely induces follicle diﬀerentiation to a postovulatory phe-
notype [113].
7. DEVELOPMENTAL AND REPRODUCTIVE TOXICITY
OF PHTHALATES IN FEMALE ANIMAL MODELS
The above-mentioned epidemiological evidence suggesting
adverse consequences for female reproductive function [30,
31] stimulated more in depth studies in animal models on
the issue. Besides causing developmental toxicity, including
high incidence of foetus death and malformations and re-
duced foetal body weight, DEHP administration to pregnant
rodents decreased embryo implantation and increased re-
sorptions [121, 122]. These eﬀects were mimicked by other
phthalate esters thus representing both male and female re-
productive toxicants in rodents [123].
The administration of phthalate esters, including DEHP
and its metabolite MEHP, to adult female rats caused an in-
crease in the estrous cycle length and dysovulation, associ-
ated with polycystic ovaries, and decreased serum levels of
estradiol[71].Thesefunctionalchangeswereassociatedwith
morphological alteration of the preovulatory follicle, the site
of estradiol production, where granulosa cells were smaller
in DEHP-treated mice than in control rats, and incapable of
mounting an ovulatory surge of LH. Regarding the molec-
ular mechanism by which DEHP/MEHP suppressed estra-
diol production in the granulosa cells, it has been found
that MEHP inhibits FSH-stimulated cAMP accumulation
and progesterone production in granulosa cells [124]. When
the progesterone precursor pregnenolone is added to granu-
losa cell cultures treated with MEHP, the inhibition of pro-
gesterone production is reversed [125]. However MEHP did
not decrease the expression of P450scc [126], the major
regulatory site of progesterone production by cAMP which
converts cholesterol to pregnenolone [127]. In addition to
reducing progesterone production at a site prior to preg-
nenolone,MEHPalsoreducesestradiolproductionbyaﬀect-
ing aromatase gene expression, the rate-limiting enzyme that
convertstestosteronetoestradiol.Aromataseisstimulatedby
FSH-mediated pathways and techal androgens. Androgens
are the substrates for aromatization to estradiol in granu-
losa cells [128] .T h u s ,M E H Pi sa b l et od e c r e a s ee s t r a d i o l
production independent of its eﬀect on FSH–cAMP and de-
creases aromatase activity without acting as a direct enzyme
inhibitor [72]. Furthermore, the induction by both DEHP
and DBP of the estradiol metabolizing enzyme 17β-HSD IV
in the liver and granulosa cells [112, 129]c o n t r i b u t e st oe x -
plainthesuppressedserumestradiol levelsafterDEHPexpo-
sure and the signiﬁcant increase in serum levels of estrone,
the primary metabolite of estradiol, observed in DBP-treated
rats [71].
Overall, these ﬁndings underline once again that ph-
thalate toxicant eﬀects on female reproductive system is at-
tributable to an interference with the complex and tightly
regulated machinery involved in steroid synthesis and
metabolism. Notably, the pathways leading to production of
ovarian hormones are similar in rodent models and humans,
and using the rodent model to determine the mechanism of
action of MEHP will aid in understanding how exposure to
this chemical may aﬀect ovarian function in women.
8. CONCLUSIONS
Phthalates are environmental contaminants with signiﬁcant
human exposures. These chemicals may act as EDCs and al-
ter reproductive function and/or cause feminization raising
concern about the potential health hazards posed by such ex-
posures. The adverse eﬀects of phthalates have been chieﬂy
studied in animal models, while their potential toxicity to
humans together with the possible involvement of PPARs in
mediating these eﬀects on the reproductive health has to be
more properly evaluated. Pre- and/or perinatal periods ap-
pear to be critical windows of exposure, because of their high
sensitivity to hormonal dysregulation by EDCs. Thus, the ac-
quisition of more detailed data on human exposure during
these time periods is essential. It has been proposed that im-
pairment of reproductive development and function in both
genders by phthalates relates to abnormal steroid biosynthe-
sis and metabolism and seems to be at least in part mediated
by the activation of the PPAR signalling pathway. Molecu-
lar basis for the adverse health eﬀects proposed to be associ-
ated with human phthalate exposure have to be elucidated.
Finally, analysis of the eﬀects of phthalate exposures on go-
nadotropin and steroid hormone levels should form part of
overall risk assessment in human populations.
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